SUPN - Supernus Pharmaceuticals: So-So Neuroscience Portfolio With ADHD Standout

2024-07-02 07:30:00 ET

Summary

• Supernus' revenue growth is hindered by rapidly declining Trokendi sales.
• There are no pipeline products reliably poised to help out with revenues.
• Qelbree provides the one bright point on Supernus' revenues.

This is my eighth Supernus ( SUPN ) article following most recently 06/2023's "Supernus: Rebuilding In Progress, But At An Inadequate Pace" (" Rebuilding "). I concluded Rebuilding by noting, "I rate Supernus as a hold. If management could amp its revenue prospects for GOCOVRI and Qelbree, it would deserve a buy, but not before."...

For further details see: